Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 47Melanoma 23Neoplasm Metastasis 19Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 13Skin Neoplasms 12Head and Neck Neoplasms 10Recurrence 9Carcinoma, Renal Cell 9Prostatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Squamous Cell 8Breast Neoplasms 8Urinary Bladder Neoplasms 7Carcinoma, Merkel Cell 7Triple Negative Breast Neoplasms 6Colonic Neoplasms 6Carcinoma, Basal Cell 6Carcinoma 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Pancreatic Neoplasms 5Stomach Neoplasms 4Sarcoma 4Multiple Myeloma 4Mouth Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4

Interventions

Cisplatin 35Radiotherapy 20Magnetic Resonance Spectroscopy 19Cetuximab 17Specimen Handling 15pembrolizumab 13Carboplatin 13Radiotherapy, Intensity-Modulated 12Fluorouracil 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Platinum 9Paclitaxel 8Surgical Procedures, Operative 7Drug Therapy 6Biopsy 6Taxes 5toripalimab 4X-Rays 4Standard of Care 4Fluorodeoxyglucose F18 4Celecoxib 4(225)Ac-DOTA-c(RGDyK) 4cemiplimab 3Nutritional Status 3Laser Therapy 3Interviews as Topic 3Hydroxyurea 3130-nm albumin-bound paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Laryngeal Neoplasms × cemiplimab × Clear all
NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
180 enrolled
Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06980038 2026-05-13

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡